Organon & Co. Announces Quarterly Dividend of $0.28 (NYSE:OGN)

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, February 13th,Wall Street Journal reports. Stockholders of record on Monday, February 24th will be paid a dividend of 0.28 per share on Thursday, March 13th. This represents a $1.12 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend is Monday, February 24th.

Organon & Co. has raised its dividend by an average of 26.0% annually over the last three years. Organon & Co. has a dividend payout ratio of 25.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $3.78 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.6%.

Organon & Co. Trading Down 6.3 %

Shares of Organon & Co. stock opened at $15.30 on Friday. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a market capitalization of $3.94 billion, a P/E ratio of 3.03, a P/E/G ratio of 0.83 and a beta of 0.76. The company has a fifty day moving average of $15.35 and a 200 day moving average of $17.48.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. On average, sell-side analysts anticipate that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OGN has been the subject of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday. Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Organon & Co. presently has a consensus rating of “Hold” and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.